Thierry Burnouf

Summary

Publications

  1. ncbi Modern plasma fractionation
    Thierry Burnouf
    Human Plasma Product Services, Lille, France
    Transfus Med Rev 21:101-17. 2007
  2. doi Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents
    Thierry Burnouf
    Research Department, Human Protein Process Sciences HPPS, 59800 Lille, France
    Anal Biochem 389:69-73. 2009
  3. doi Blood-derived biomaterials and platelet growth factors in regenerative medicine
    Thierry Burnouf
    Institute of Medical Biomaterials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Taiwan
    Blood Rev 27:77-89. 2013
  4. ncbi Reducing the risk of infection from plasma products: specific preventative strategies
    T Burnouf
    Human Plasma Product Services HPPS, Lille, France
    Blood Rev 14:94-110. 2000
  5. doi A chromatographically purified human TGF-β1 fraction from virally inactivated platelet lysates
    T Burnouf
    Human Protein Process Sciences HPPS, Lille, France
    Vox Sang 101:215-20. 2011
  6. doi Recombinant plasma proteins
    T Burnouf
    Human Protein Process Sciences, Lille, France
    Vox Sang 100:68-83. 2011
  7. doi Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems
    T Burnouf
    Human Plasma Product Services, Research Department, Lille, France
    Haemophilia 14:956-62. 2008
  8. doi [Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems]
    T Burnouf
    Human Protein Process Sciences, Research and Development, 18, rue Saint Jacques, 59000 Lille, France
    Transfus Clin Biol 15:129-34. 2008
  9. ncbi Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma
    Thierry Burnouf
    Research Department, Human Plasma Product Services, 18 rue Saint Jacques, 59800 Lille, France
    Biologicals 35:349-53. 2007
  10. ncbi [Plasma fractionation in the world: current status]
    T Burnouf
    Human Plasma Product Services HPPS, 18 rue Saint Jacques, 59000 Lille, France
    Transfus Clin Biol 14:41-50. 2007

Collaborators

  • Jerard Seghatchian
  • Hadi Alphonse Goubran
  • Daniel Tzu Bi Shih
  • Claudine Caron
  • Regis Bordet
  • Chun Ching Lin
  • M Radosevich
  • T Sato
  • Jose Maria Gutierrez
  • J Goudemand
  • S Chtourou
  • Jean Pierre Cazenave
  • Ming Li Chou
  • Ching Li Tseng
  • Yu Wen Wu
  • Liang Tzung Lin
  • Chen Yao Su
  • Flore Gouel
  • Ying Jan Weng
  • Yu Chun Kao
  • Shun Hung Hsiao
  • Andy Bailey
  • Junji Tanimoto
  • David Devos
  • Hsiu Chen Lin
  • Yueh Lun Lee
  • Pierre Alain Burnouf
  • Jean Christophe Devedjian
  • Anne Husebekk
  • Aurélie Jonneaux
  • Ting Yi Renn
  • Caroline Moreau
  • Bernhard Samminger
  • Zhi yu Chen
  • METTE KJAER
  • Bjorn Skogen
  • Bruce Do Van
  • Tiffany Avory
  • Christopher D Richardson
  • Shun Pang Chang
  • Hui Wen Chang
  • Ting Chun Hung
  • Jérôme Champagne
  • René Gantier
  • Magali Toueille
  • Tsung Jen Wang
  • Ying Hua Shieh
  • Yi Yuan Yang
  • Lin Wen Lee
  • George Hsiao
  • Sy Jye Leu
  • Po Kai Juan
  • Yu Hung Tseng
  • Ya Po Kuo
  • Ching Hua Su
  • F Kouoh Elombo
  • Kai Wei Lin
  • Chao Ching Chiang
  • Wen Fu Lai
  • C Mizon
  • J P Catteau
  • N Cotelle
  • J Descamps
  • J L Bernier
  • M Poulle
  • C Michalski
  • D Albani
  • J Mizon
  • M Balduyck

Detail Information

Publications52

  1. ncbi Modern plasma fractionation
    Thierry Burnouf
    Human Plasma Product Services, Lille, France
    Transfus Med Rev 21:101-17. 2007
    ..In a regulated and professional environment, fractionated plasma products manufactured by modern processes are certainly among the lowest-risk therapeutic biological products in use today...
  2. doi Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents
    Thierry Burnouf
    Research Department, Human Protein Process Sciences HPPS, 59800 Lille, France
    Anal Biochem 389:69-73. 2009
    ..66 g/7 ml of IgG, corresponding to a binding capacity of approximately 106 mg of Triton X-100/g of dry SDR HyperD. Good recoveries of IVIG were achieved in the effluent from both sorbents...
  3. doi Blood-derived biomaterials and platelet growth factors in regenerative medicine
    Thierry Burnouf
    Institute of Medical Biomaterials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Taiwan
    Blood Rev 27:77-89. 2013
    ..We present the scientific rationale that prevailed in the development of blood biomaterials, describe their modes of production and biochemical and functional characteristics, and present clinical applications in regenerative medicine...
  4. ncbi Reducing the risk of infection from plasma products: specific preventative strategies
    T Burnouf
    Human Plasma Product Services HPPS, Lille, France
    Blood Rev 14:94-110. 2000
    ..Nevertheless, the vulnerability of the plasma supply to new infectious agents requires continuous vigilance so that rational and appropriate scientific countermeasures against emerging infectious risks can be implemented promptly...
  5. doi A chromatographically purified human TGF-β1 fraction from virally inactivated platelet lysates
    T Burnouf
    Human Protein Process Sciences HPPS, Lille, France
    Vox Sang 101:215-20. 2011
    ..TGF-β1 exerts important physiological functions in osteogenesis and chondrogenesis and may be of therapeutic interest. The aim of this work was to develop a scalable purification process of TGF-β1 from virally inactivated human platelets...
  6. doi Recombinant plasma proteins
    T Burnouf
    Human Protein Process Sciences, Lille, France
    Vox Sang 100:68-83. 2011
    ....
  7. doi Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems
    T Burnouf
    Human Plasma Product Services, Research Department, Lille, France
    Haemophilia 14:956-62. 2008
    ..The anti-A and anti-B titre was 0-1 and 0-1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen...
  8. doi [Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems]
    T Burnouf
    Human Protein Process Sciences, Research and Development, 18, rue Saint Jacques, 59000 Lille, France
    Transfus Clin Biol 15:129-34. 2008
    ..A single-use SD treatment and SD-elimination system is currently under development to allow standardized use of the procedure by blood establishments or national or regional service centers...
  9. ncbi Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma
    Thierry Burnouf
    Research Department, Human Plasma Product Services, 18 rue Saint Jacques, 59800 Lille, France
    Biologicals 35:349-53. 2007
    ..The choice of detergents for the SD viral inactivation of therapeutic plasma fractions used in patients at risk of fibrinolysis should consider the impact on alpha2-AP activity...
  10. ncbi [Plasma fractionation in the world: current status]
    T Burnouf
    Human Plasma Product Services HPPS, 18 rue Saint Jacques, 59000 Lille, France
    Transfus Clin Biol 14:41-50. 2007
    ..In the last few years, the plasma fractionation industry has improved greatly, and should remain essential in the years to come for the procurement of many essential medicines...
  11. ncbi Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms
    Thierry Burnouf
    Human Plasma Product Services, 18 rue Saint Jacques, F 59000 Lille, France
    Biologicals 35:329-34. 2007
    ..Therefore the current manufacturing processes of at least some animal antisera already include production steps that can ensure robust viral inactivation of LE viruses and moderate inactivation of a NLE virus...
  12. ncbi Current strategies to prevent transmission of prions by human plasma derivatives
    T Burnouf
    Human Plasma Product Services HPPS, 18, rue Saint Jacques, 59000 Lille, France
    Transfus Clin Biol 13:320-8. 2006
    ..Therefore, the risk of transmission of vCJD by human plasma products appears remote, but caution should prevail since the biochemical nature of the infectious agent in human blood is still unknown...
  13. ncbi A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system
    Thierry Burnouf
    Human Plasma Product Services, Lille, France
    Transfusion 46:2100-8. 2006
    ..Two S/D treatment procedures for single donations or minipools of plasma have been developed with a single-use bag system...
  14. ncbi Assessment of the viral safety of antivenoms fractionated from equine plasma
    Thierry Burnouf
    Human Plasma Product Services, 18 rue Saint Jacques, F 59000 Lille, France
    Biologicals 32:115-28. 2004
    ....
  15. ncbi Affinity chromatography in the industrial purification of plasma proteins for therapeutic use
    T Burnouf
    Human Plasma Product Services, 18 rue Saint Jacques, 59800 Lille, France
    J Biochem Biophys Methods 49:575-86. 2001
    ..Both approaches may lead to the development of tailor-made synthetic ligands that would allow implementation of protein capture technology, providing improved productivity and yield for plasma products...
  16. ncbi Nanofiltration of plasma-derived biopharmaceutical products
    T Burnouf
    Human Plasma Product Service, Lille, France
    Haemophilia 9:24-37. 2003
    ..Nanofiltration is increasingly becoming a routine step in the manufacture of biopharmaceutical products...
  17. ncbi Nanofiltration of single plasma donations: feasibility study
    T Burnouf
    Human Plasma Product Services, Lille, France
    Vox Sang 84:111-9. 2003
    ..The present study was performed to assess, for the first time, the feasibility of applying a nanofiltration process, using 75-nm and 35-nm mean pore size membranes (Planova) 75N and Planova 35N), to human plasma...
  18. ncbi Protein composition and activation markers in plasma collected by three apheresis procedures
    Thierry Burnouf
    Human Plasma Product Services, Lille, France
    Transfusion 43:1223-30. 2003
    ....
  19. ncbi Residual cell content in plasma produced by three centrifugal apheresis procedures
    Thierry Burnouf
    Human Plasma Product Services, Lille, France
    Transfusion 43:1522-6. 2003
    ....
  20. ncbi Content and functional activity of von Willebrand factor in apheresis plasma
    T Burnouf
    Human Plasma Product Services, Lille, France
    Vox Sang 87:27-33. 2004
    ..We studied VWF content, functional activity and HMW multimers in plasmas collected by five different automated apheresis collection procedures...
  21. ncbi Assessment of complement activation during membrane-based plasmapheresis procedures
    Thierry Burnouf
    Human Plasma Product Services, Lille, France
    J Clin Apher 19:142-7. 2004
    ..Further studies are needed to explain differences in complement activation between apheresis procedures and to assess clinical impacts, if any...
  22. ncbi A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system
    T Burnouf
    Human Plasma Product Services, Lille, France
    Vox Sang 91:56-62. 2006
    ..As cryoprecipitate may be contaminated with pathogenic plasma-borne viruses, there is an urgent need to develop a simple method for the viral inactivation of cryoprecipitate...
  23. doi Human blood-derived fibrin releasates: composition and use for the culture of cell lines and human primary cells
    Thierry Burnouf
    Human Protein Process Sciences HPPS, Research Department, Lille, France and College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
    Biologicals 40:21-30. 2012
    ....
  24. doi A virally inactivated platelet-derived growth factor/vascular endothelial growth factor concentrate fractionated from human platelets
    Thierry Burnouf
    Human Protein Process Sciences, Research Department, Lille, France
    Transfusion 50:1702-11. 2010
    ..Human platelet concentrates (PCs) may be a source material to produce purified growth factors (GFs) for clinical use or cell therapy. However, no fractionation process of therapeutic-grade GF from PCs has ever been developed...
  25. doi Solvent/detergent treatment of platelet concentrates enhances the release of growth factors
    Thierry Burnouf
    Human Plasma Product Services, Research Department, Lille, France
    Transfusion 48:1090-8. 2008
    ..If allogeneic products are to be used for clinical or cell culture applications, a method of viral inactivation of the PC source of growth factors is desirable...
  26. doi Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich plasma, PLT gel, and solvent/detergent-treated PLT lysate biomaterials against wound bacteria
    Thierry Burnouf
    College of Oral Medicine and the Department of Microbiology and Immunology, Taipei Medical University, Taipei, Taiwan
    Transfusion 53:138-46. 2013
    ..Platelet (PLT) gels exhibit antimicrobial activity useful for wound healing. The nature of the antibacterial component(s) is unknown...
  27. doi Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor
    Thierry Burnouf
    College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
    Transfusion 52:1721-8. 2012
    ..We have developed PLT viral inactivation and chromatographic fractionation processes and decided here to identify fractions enriched in BDNF...
  28. doi Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG
    Yu Wen Wu
    Institute of Medical Biomaterials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan Research and Development, Chromatography Applications, Pall Life Sciences, Cergy, France Pall Life Sciences, Northborough, Massachusetts Human Protein Process Sciences HPPS, Lille, France
    Transfusion 54:169-78. 2014
    ..Some adverse events are due to contaminants like IgA and activated Factor (F)XI. Therefore, new purification strategies are needed for dedicated removal of these contaminants without impairing IgG recovery...
  29. doi Virally inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model
    Yueh Lun Lee
    Department of Microbiology and Immunology, College of Medicine, School of Medical Laboratory Science and Biotechnology, Taipei, Taiwan Department of Pharmacology, College of Medicine, School of Medical Laboratory Science and Biotechnology, Taipei, Taiwan College of Oral Medicine, Taipei Medical University, Taipei, Taiwan Department of Dentistry, National Yang Ming University, Taipei, Taiwan Department of Family Medicine, Taipei Medical University, Wan Fang Hospital, Taipei, Taiwan Research department, Human Protein Process Science, Lille, France
    Transfusion 53:1918-28. 2013
    ..The functional properties of this preparation should be unveiled. We hypothesized that, due to transforming growth factor-β1 (TGF-β1) content, PCLs may exert immunosuppressive and anti-inflammatory functions...
  30. doi Expansion of adipose tissue mesenchymal stromal progenitors in serum-free medium supplemented with virally inactivated allogeneic human platelet lysate
    Daniel Tzu Bi Shih
    Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan
    Transfusion 51:770-8. 2011
    ..Recently, we have developed a solvent/detergent (S/D)-treated human PL preparation (S/D-PL) rich in growth factors. The capacity to use this virally inactivated preparation for MSC expansion needs to be evaluated...
  31. doi A novel virally inactivated human platelet lysate preparation rich in TGF-beta, EGF and IGF, and depleted of PDGF and VEGF
    Pierre Alain Burnouf
    Human Protein Process Sciences, 59 800 Lille, France
    Biotechnol Appl Biochem 56:151-60. 2010
    ..Our results open up the possibility to evaluate the potential of this new preparation for stem cell expansion and/or bone tissue engineering and regeneration...
  32. ncbi Chromatographic purification and properties of a therapeutic human protein C concentrate
    M Radosevich
    Centre Régional de Transfusion Sanguine de Lille, 21, rue Camille Guérin, 59000, Lille, France
    J Chromatogr B Analyt Technol Biomed Life Sci 790:199-207. 2003
    ..Therefore, this concentrate appears to be of potential benefit for the treatment of protein C deficiency...
  33. doi Nanofiltration to remove microparticles and decrease the thrombogenicity of plasma: in vitro feasibility assessment
    Ming Li Chou
    Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
    Transfusion 55:2433-44. 2015
    ..As plasma contains procoagulant microparticles (MPs), removing MPs by 75-nm nanofiltration may decrease plasma in vitro thrombogenicity while maintaining the hemostatic activity from coagulation factors...
  34. doi Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine
    Thierry Burnouf
    Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan Electronic address
    Blood Rev 28:155-66. 2014
    ..Finally we review the potential function of PMPs in tissue regeneration and the prospects for their use in therapeutic strategies for human health...
  35. doi The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways
    Flore Gouel
    Department of Medical Pharmacology INSERM U1171, Lille Faculty of Medicine, Lille University Medical Center and Lille Nord de France University, Lille, France
    J Tissue Eng Regen Med . 2016
    ..Copyright © 2016 John Wiley & Sons, Ltd...
  36. doi Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion
    Yu Chun Kao
    Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
    Cytotherapy 18:911-24. 2016
    ....
  37. doi Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine
    Yu Wen Wu
    Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
    Transfus Apher Sci 54:309-18. 2016
    ....
  38. pmc Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome
    Ching Li Tseng
    Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
    PLoS ONE 11:e0153573. 2016
    ..In conclusion, this preclinical study supports the possibility of using S/D virally inactivated SEDs to treat DES and restore a normal epithelium. ..
  39. doi Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro
    Hsiu Chen Lin
    Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei, Taiwan
    Transfus Apher Sci 53:246-52. 2015
    ..Controlling the impact of the presence of PMPs in transfused blood components in certain patient population or critically ill patients deserves in-depth consideration...
  40. doi Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance
    M Radosevich
    Human Protein Process Sciences, Lille, France
    Vox Sang 98:12-28. 2010
    ....
  41. pmc Anti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
    Ying Jan Weng
    Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
    PLoS ONE 11:e0162973. 2016
    ..Clinical-grade HPA-1a IgG can be prepared using a process compliant with current quality requirements opening perspectives for the prevention of FNAIT. ..
  42. doi Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believing
    Ching Li Tseng
    Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan
    Transfus Apher Sci 53:95-8. 2015
    ..This relatively mild treatment results in moderate DES pathology, with a stable shortage of tear secretion throughout a 7-week study period, which we found suitable for assessing efficacy of serum eye drops. ..
  43. pmc Removal of transmissible spongiform encephalopathy prion from large volumes of cell culture media supplemented with fetal bovine serum by using hollow fiber anion-exchange membrane chromatography
    Ming Li Chou
    Graduate Institute of Medical Science, College of Medicine, Taipei Medical University, Taipei, Taiwan
    PLoS ONE 10:e0122300. 2015
    ....
  44. ncbi “Go no Go” in plasma fractionation in the world’s emerging economies: still a question asked 70 years after the COHN process was developed!
    Thierry Burnouf
    Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
    Transfus Apher Sci 51:113-9. 2014
    ..are still increasing, despite increasing use of recombinant products, and attention is being focused on the five Ws of the fractionation field: which products; where; when; what and how much; and who will be the main suppliers?..
  45. ncbi Ebola virus convalescent blood products: where we are now and where we may need to go
    Thierry Burnouf
    Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
    Transfus Apher Sci 51:120-5. 2014
    ..The preparation of minipool immunoglobulins is also a realistic option to consider...
  46. pmc TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus
    Ming Li Chou
    Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
    PLoS ONE 10:e0117800. 2015
    ..We propose that the methodology used here to study HCV infectivity can be valuable in the validation of viral inactivation and removal processes of human plasma-derived products. ..
  47. doi Multifaceted regenerative lives of expired platelets in the second decade of the 21st century
    Thierry Burnouf
    Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan Electronic address
    Transfus Apher Sci 51:107-12. 2014
    ..However, strong evidence accumulates toward a potential for further manufacturing avenues of expired platelet concentrates into valuable therapeutic and clinically relevant products. ..
  48. doi Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion
    Daniel Tzu Bi Shih
    Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan Pediatrics Department, Taipei Medical University Hospital, Taipei, Taiwan
    N Biotechnol 32:199-211. 2015
    ..Produced under optimal conditions of standardization and safety, human platelet materials can become the future 'gold standard' supplement for ex vivo production of MSCs for translational medicine and cell therapy applications. ..
  49. pmc Ex vivo expansion of bovine corneal endothelial cells in xeno-free medium supplemented with platelet releasate
    Ming Li Chou
    Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan, R O C
    PLoS ONE 9:e99145. 2014
    ..These findings open a new paradigm for ex vivo propagation protocols of corneal endothelium cells in compliance with good tissue culture practices and regulatory recommendations to limit the use of xenogenic materials. ..
  50. ncbi Purification of human ceruloplasmin as a by-product of C1-inhibitor
    F Kouoh Elombo
    Faculte des Sciences Pharmaceutiques et Biologiques, Laboratoire de Pharmacologie, Pharmacocinetique et Pharmacie Clinique, Lille, France
    Biol Pharm Bull 23:1406-9. 2000
    ..20 and 2.21). Purified Cp has a specific activity of 24.5+/-0.2 mU/mg of proteins. This process provides a method for Cp purification that could be easily integrated into modern plasma fractionation...
  51. ncbi Development of an enzyme-linked immunosorbent assay for human plasma inter-alpha-trypsin inhibitor (ITI) using specific antibodies against each of the H1 and H2 heavy chains
    C Mizon
    Laboratoire de Biochimie, Faculte de Pharmacie, Lille, France
    J Immunol Methods 190:61-70. 1996
    ..5-506). The high specificity, sensitivity, reproducibility and accuracy of the present assay should facilitate the specific measurement of native ITI in blood and thus might represent a useful tool for further physiopathological studies...
  52. ncbi Platelet-derived growth factor-AB and transforming growth factor-beta 1 in platelet gels activated by single-donor human thrombin
    Chen Yao Su
    Transfusion 44:945. 2004